DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Alphabet is the mother company of Google. Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic ...

Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google's parent company Alphabet, failed to meet its primary endpoint, according ...

Google’s (GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug. Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...

Calico ignited the race by drug companies to find treatments for aging-related diseases. An ALS-fighting drug from Calico Life Sciences LLC — the Alphabet-backed anti-aging company founded by ...

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for Unspecified ...

About 300 young people engaged in multiple fights in a Wānaka park last night. Otago Lakes area police said they were called to Dinosaur Park about midnight after reports of fights. "At least three ...